Biocytogen Announces RenLite® Licensing Agreement with Janssen
8.3.2023 16:25:00 EET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.
RenLite® is a member of Biocytogen's fully human antibody RenMice™ family. RenLite® mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite® discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.
Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.”
About RenMice™
RenMice™ are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab™, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.
As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005504/en/
Contact information
Biocytogen’s Contacts
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting Deepens Advisory Solutions in Turkey with ODS Consulting Group14.7.2026 16:30:00 EEST | Press release
Andersen Consulting adds collaborating firm ODS Consulting Group, enhancing its platform across digital transformation, talent strategy, and operational advisory services. Founded in 2008 and headquartered in Turkey, ODS Consulting Group provides advisory services to organizations seeking growth, talent, and investment opportunities in Turkey and international markets. The firm supports clients through international business development and export consulting, recruitment and talent management solutions, and investment advisory services, helping businesses expand operations, access new markets, attract qualified talent, and navigate the Turkish business landscape. With a multidisciplinary approach and deep local expertise, ODS delivers tailored strategies that drive sustainable growth and long-term value creation. “Since our founding, we have focused on helping organizations build sustainable growth through a combination of strategic insight and practical execution,” said Onur Seçkin, c
IAMPHENOM Europe 2026 Speaker Lineup Focuses on Practitioners Redesigning HR Operations with AI, Agents and Automation14.7.2026 16:30:00 EEST | Press release
Phenom, the leader in applied AI built to redesign work operations for hiring faster, developing better and retaining longer, today announced the first wave of speakers for IAMPHENOM Europe 2026, the only applied AI event dedicated to human resources taking place on 4-5 November in Paris, France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714617871/en/ Phenom today announced the first wave of speakers for IAMPHENOM Europe 2026, the only applied AI event dedicated to human resources taking place on 4-5 November in Paris, France. At the two-day in-person event, HR professionals, talent acquisition and talent management leaders, HRIT teams and C-suite executives will experience unparalleled immersive AI learning and networking. Attendees will gain actionable strategies from the organisations already using agents and automation to improve work operations and strengthen hiring, development and retention, while connecting w
RealPage Acquires Cherre, Creating a Trusted AI-Powered Intelligence Platform Across the Full Real Estate Capital Stack14.7.2026 16:03:00 EEST | Press release
RealPage, Inc., a leading provider of AI-enabled software and data analytics to the real estate industry, today announced it has completed its acquisition of Cherre, a real estate data intelligence company trusted by institutional owners, investment managers, and operators worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714560587/en/ RealPage now with Cherre. "AI can transform real estate only if it understands real estate," said Dirk Wakeham, President and Chief Executive Officer of RealPage. "Cherre has built the kind of trusted, governed intelligence that institutional owners and asset managers depend on. Bringing that expertise into RealPage means every customer, whether they manage one property or a global portfolio, gets access to a stronger, more trustworthy foundation for their decisions.” "We've always believed real estate organizations can't make confident decisions on data alone. They need a trusted,
Statement on Terminating the Letter of Intent With AI Financial Corporation14.7.2026 16:00:00 EEST | Press release
Statement from Matthew Nicoletti, Chief Strategy Officer, Perpetuals.com (Nasdaq: PDC), on the proposed transaction with AI Financial Corporation. “Perpetuals has decided not to further pursue the acquisition of AI Financial Corporation’s subsidiary Alt5 Sigma Canada, Inc. and the earlier letter of intent has been terminated.” About Perpetuals.com Ltd Perpetuals.com Ltd (Nasdaq: PDC) is a fintech company developing AI-powered trading products and prediction markets, with a global footprint across the United States, Europe, and Asia. Its mission is to reduce risk through empowering retail users with intuitive, secure, and efficient trading experiences that span the world’s capital markets. UpsideOnly, the company's flagship consumer product, is the first risk-free trading platform, pairing human market insight with proprietary BayesShield AI so users can share in trading profits without ever risking their own money. Perpetuals’s proprietary AI system, BayesShield AI, combines advanced A
VIVERE Group Selects Rimini Street to Strengthen SAP Support and Accelerate Business Transformation14.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced VIVERE Group, a leading Indonesian one-stop solution provider for interior contracting, furniture manufacturing and furnishing, has selected Rimini Support™ for SAP to help maintain business continuity, strengthen support for its critical SAP ECC environment and free internal IT resources to focus on digital transformation initiatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714644251/en/ VIVERE Group Selects Rimini Street to Strengthen SAP Support and Accelerate Business Transformation Strengthening SAP support while advancing transformation Founded in 1984 and listed on the Indonesia Stock Exchange since 2002, PT Gema Graham Sarana Tbk (IDX: GEMA) has grown into the core company of VIVERE Group, running SAP ECC 6 on IBM Db2 as a crit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom